mobile nav toggler

investors

Provention Bio, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics aimed at intercepting and preventing immune-mediated diseases. Our mission is to in-license, transform and develop clinical-stage, or nearly clinical-stage, therapeutic candidates targeting the high morbidity, mortality and escalating costs of autoimmune and inflammatory diseases.

DOWNLOAD THE LATEST PRESENTATION

recent releases
Aug 3, 2020

Provention Bio, Inc., (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced the appointment of Heidy Abreu King-Jones to the...

Jul 30, 2020

Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it will report its second...

Jun 30, 2020

Provention Bio, Inc., (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced today a change in the format of its 2020 Annual...

View All Releases >

current stock price
NASDAQPRVB
NASDAQPRVB

investor relations contacts

For more information contact Sam Martin
Argot Partners, 212.600.1902 

EMAIL SAM

Sign Up For Email Alerts